Gilead Sciences, Inc. (GILD) Tops Q1 EPS by 61c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Gilead Sciences (GILD) Q1 Results Called 'Outstanding' at Wells Fargo
April 23, 2014 9:36 AM EDTWells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $87-$91. Analyst Brian Abrahams described Q1 results as "outstanding."
"On 4/22, GILD reported outstanding quarterly results, with Sovaldi sales likely exceeding most sell/buyside expectations, some... More
Gilead (GILD) Q1 'One of Most Impressive Beats in Biopharma History' - Piper Jaffray
April 23, 2014 8:51 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Gilead Sciences (NASDAQ: GILD) and bumped his price target price target from $105 to $106 following impressive Q1 results and said the stock is officially a 'value' stock.
Schimmer comments, "GILD reported one of the... More
Goldman Sachs Comments on Gilead Sciences (GILD) Q1
April 23, 2014 7:46 AM EDTGoldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $65.00 (from $63.00).
Analyst Terence Flynn said, "Sovaldi posted an impressive beat in its first full quarter on the US market... More
Gilead Sciences (GILD) Q1 'As Good as it Gets' - Nomura
April 23, 2014 7:39 AM EDTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) from $121 to $130 calling Q1 'as good as it gets.'
We are raising our HCV sales estimates and target price to $130 from $121 following... More
